Teladoc Health (NYSE:TDOC) Announces Quarterly Earnings Results

Teladoc Health (NYSE:TDOC) posted its earnings results on Wednesday. The health services provider reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07), Zacks reports. The firm had revenue of $640.49 million for the quarter, compared to analysts’ expectations of $639.44 million. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. Teladoc Health updated its Q1 2025 guidance to -0.400–0.150 EPS and its FY 2025 guidance to -1.100–0.500 EPS.

Teladoc Health Stock Performance

Shares of NYSE TDOC opened at $9.22 on Friday. The firm’s 50-day moving average price is $10.62 and its 200-day moving average price is $9.53. Teladoc Health has a 52-week low of $6.76 and a 52-week high of $15.95. The company has a market cap of $1.59 billion, a PE ratio of -1.61 and a beta of 1.04. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66.

Insider Activity

In other news, insider Carlos Nueno sold 2,389 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $11.93, for a total value of $28,500.77. Following the transaction, the insider now directly owns 2,890 shares in the company, valued at $34,477.70. This trade represents a 45.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.95% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

TDOC has been the topic of a number of recent research reports. TD Cowen reduced their target price on shares of Teladoc Health from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Thursday, October 31st. The Goldman Sachs Group upped their price objective on shares of Teladoc Health from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Teladoc Health from $10.00 to $12.00 and gave the company a “hold” rating in a report on Friday, November 1st. Barclays upped their price target on Teladoc Health from $10.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Finally, Royal Bank of Canada raised their price objective on Teladoc Health from $11.00 to $12.00 and gave the company an “outperform” rating in a research report on Friday, January 24th. Eleven analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $11.44.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.